Growth Hormone SecretagoguesWADA Prohibited
GHRP-2
Synonyms: Pralmorelin, Growth Hormone Releasing Peptide-2
Sequence: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Critical Safety & Regulatory Notice
GHRP-2 is classified as a regulated, unapproved, or research-only substance. Doping/Regulatory Status: Approved as a diagnostic agent in Japan. Not FDA approved. Prohibited by WADA.. Clinical safety profiles for human use are deficient or not approved.
History & Discovery Timeline
GHRP-2 was synthesized in the early 1990s by Dr. Cyril Bowers and colleagues as a potent, second-generation GH-releasing peptide.
What it is: It is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) ghrelin receptor agonist. It falls under the Metabolic category.
Proposed Mechanisms & Research Findings: It activates the ghrelin receptor, stimulating robust growth hormone secretion while also causing mild increases in prolactin and cortisol levels.
Regulatory & Safety Status: It is not FDA approved. It is restricted to laboratory and clinical trials. Online gray-market sourcing carries significant purity risks.
Athletic & Anti-Doping Status: Strictly prohibited by WADA under Section S2. Detection results in immediate suspension.
Understanding GHRP-2 Key Facts
Primary Target System:NEUROENDOCRINE
Residue Count / Length:11 Amino Acids
Primary Action & Category:Ghrelin Receptor Agonist (Growth Hormone Secretagogues)
Primary Receptors:Growth Hormone Secretagogue Receptor 1a (GHSR-1a)
Figure 1: Detailed molecular mechanism pathways of GHRP-2 (click to enlarge).